5 ETFs to Make the Most of Eli Lilly's Strength
Eli Lilly's Strong Q2 Performance: Eli Lilly reported impressive second-quarter results for 2024, with earnings per share of $3.92 and revenues of $11.3 billion, driven by significant sales growth in diabetes and weight-loss drugs, leading to a 9.5% increase in shares post-announcement.
Increased Outlook and ETF Opportunities: Following the strong earnings, Eli Lilly raised its full-year revenue guidance and several analysts upgraded their stock targets; investors are encouraged to consider ETFs with high exposure to Eli Lilly, such as iShares U.S. Pharmaceuticals ETF and Roundhill GLP-1 & Weight Loss ETF.
Trade with 70% Backtested Accuracy
Analyst Views on MEDX
No data
About the author
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly's Q2 Performance: Eli Lilly reported strong second-quarter results for 2025, exceeding earnings and revenue estimates due to high demand for its diabetes and weight-loss drugs, leading to an increased full-year outlook. However, shares fell 14% following disappointing data on a new weight-loss pill, orforglipron.
ETF Investment Opportunities: Investors looking to capitalize on Eli Lilly's performance can consider various ETFs with significant exposure to the company, including iShares U.S. Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, and Roundhill GLP-1 & Weight Loss ETF, among others.
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Eli Lilly's Stock Performance: Eli Lilly has seen a year-to-date increase of 32.11%, impacting various ETFs differently, with some experiencing gains and others declines in their YTD performance.
Strategic Investments and Growth Plans: The company announced a $15 billion share buyback and a $3 billion expansion of its manufacturing facility as part of a broader $23 billion investment to enhance production capabilities for diabetes and obesity treatments.
5 ETFs to Make the Most of Eli Lilly's Strength
Eli Lilly's Strong Q2 Performance: Eli Lilly reported impressive second-quarter results for 2024, with earnings per share of $3.92 and revenues of $11.3 billion, driven by significant sales growth in diabetes and weight-loss drugs, leading to a 9.5% increase in shares post-announcement.
Increased Outlook and ETF Opportunities: Following the strong earnings, Eli Lilly raised its full-year revenue guidance and several analysts upgraded their stock targets; investors are encouraged to consider ETFs with high exposure to Eli Lilly, such as iShares U.S. Pharmaceuticals ETF and Roundhill GLP-1 & Weight Loss ETF.
Alltrna Announces Updates to Its Board of Directors
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
- FDA Advisory Committee Recommendation: The FDA's PCNS Advisory Committee voted unanimously to recommend the approval of Eli Lilly's Alzheimer's drug, donanemab, citing substantial evidence of efficacy and disease progression slowdown.
- Alzheimer's Drug Approvals: Biogen's Leqembi was approved in the U.S. last year for early Alzheimer's disease, while Aduhelm faced discontinuation due to low sales. Prothena, AC Immune, and Cassava Sciences are also developing Alzheimer's therapies.
- Market Outlook: The global Alzheimer's Disease Therapeutics Market is projected to exceed $30.8 billion by 2033 with a CAGR of 18.8%, led by North America. Asia-Pacific is expected to see significant growth.
- Investment Opportunities: Investors interested in Alzheimer's drug approvals can consider Lilly stock or ETFs like iShares U.S. Pharmaceuticals ETF, Roundhill GLP-1 & Weight Loss ETF, Horizon Kinetics Medical ETF, and Amplify Weight Loss Drug & Treatment ETF.
- Risks and Warnings: Donanemab and Leqembi carry warnings for amyloid-related imaging abnormalities (ARIA), and the FDA has not set a decision date for donanemab following the advisory meeting delay.
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly's Q2 Performance: Eli Lilly reported strong second-quarter results for 2025, exceeding earnings and revenue estimates due to high demand for its diabetes and weight-loss drugs, leading to an increased full-year outlook. However, shares fell 14% following disappointing data on a new weight-loss pill, orforglipron.
ETF Investment Opportunities: Investors looking to capitalize on Eli Lilly's performance can consider various ETFs with significant exposure to the company, including iShares U.S. Pharmaceuticals ETF, VanEck Vectors Pharmaceutical ETF, and Roundhill GLP-1 & Weight Loss ETF, among others.
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Eli Lilly's Stock Performance: Eli Lilly has seen a year-to-date increase of 32.11%, impacting various ETFs differently, with some experiencing gains and others declines in their YTD performance.
Strategic Investments and Growth Plans: The company announced a $15 billion share buyback and a $3 billion expansion of its manufacturing facility as part of a broader $23 billion investment to enhance production capabilities for diabetes and obesity treatments.
5 ETFs to Make the Most of Eli Lilly's Strength
Eli Lilly's Strong Q2 Performance: Eli Lilly reported impressive second-quarter results for 2024, with earnings per share of $3.92 and revenues of $11.3 billion, driven by significant sales growth in diabetes and weight-loss drugs, leading to a 9.5% increase in shares post-announcement.
Increased Outlook and ETF Opportunities: Following the strong earnings, Eli Lilly raised its full-year revenue guidance and several analysts upgraded their stock targets; investors are encouraged to consider ETFs with high exposure to Eli Lilly, such as iShares U.S. Pharmaceuticals ETF and Roundhill GLP-1 & Weight Loss ETF.
Alltrna Announces Updates to Its Board of Directors
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
- FDA Advisory Committee Recommendation: The FDA's PCNS Advisory Committee voted unanimously to recommend the approval of Eli Lilly's Alzheimer's drug, donanemab, citing substantial evidence of efficacy and disease progression slowdown.
- Alzheimer's Drug Approvals: Biogen's Leqembi was approved in the U.S. last year for early Alzheimer's disease, while Aduhelm faced discontinuation due to low sales. Prothena, AC Immune, and Cassava Sciences are also developing Alzheimer's therapies.
- Market Outlook: The global Alzheimer's Disease Therapeutics Market is projected to exceed $30.8 billion by 2033 with a CAGR of 18.8%, led by North America. Asia-Pacific is expected to see significant growth.
- Investment Opportunities: Investors interested in Alzheimer's drug approvals can consider Lilly stock or ETFs like iShares U.S. Pharmaceuticals ETF, Roundhill GLP-1 & Weight Loss ETF, Horizon Kinetics Medical ETF, and Amplify Weight Loss Drug & Treatment ETF.
- Risks and Warnings: Donanemab and Leqembi carry warnings for amyloid-related imaging abnormalities (ARIA), and the FDA has not set a decision date for donanemab following the advisory meeting delay.
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
